Osteopenia Associated with Increased Prolactin and Aging in Psychiatric Patients Treated with Prolactin-elevating Antipsychotics
Overview
Affiliations
The aim of this study was to determine the prevalence of osteopenia in schizophrenic patients with hyperprolactinemia and to identify factors influencing bone density. Our results indicate that low bone mineral density was highly prevalent in a chronic psychiatric population treated with prolactin-elevating antipsychotics. Identified risk factors appear to be age and hyperprolactinemia for both females and males.
Nikolic T, Petronijevic M, Sopta J, Velimirovic M, Stojkovic T, Jevtic Dozudic G BMC Pharmacol Toxicol. 2017; 18(1):65.
PMID: 29020988 PMC: 5637335. DOI: 10.1186/s40360-017-0171-4.
Dogan Bulut S, Bulut S, Tuzer V, Ak M, Ak E, Kisa C Noro Psikiyatr Ars. 2017; 51(3):205-210.
PMID: 28360627 PMC: 5353124. DOI: 10.4274/npa.y6628.
Chen C, Lane H, Lin C Clin Psychopharmacol Neurosci. 2016; 14(3):238-49.
PMID: 27489377 PMC: 4977815. DOI: 10.9758/cpn.2016.14.3.238.
Osteoporosis and fracture risk in people with schizophrenia.
Kishimoto T, De Hert M, Carlson H, Manu P, Correll C Curr Opin Psychiatry. 2012; 25(5):415-29.
PMID: 22744405 PMC: 3566242. DOI: 10.1097/YCO.0b013e328355e1ac.
Effect of age and disease on bone mass in Japanese patients with schizophrenia.
Sugawara N, Yasui-Furukori N, Umeda T, Tsuchimine S, Fujii A, Sato Y Ann Gen Psychiatry. 2012; 11:5.
PMID: 22348381 PMC: 3298460. DOI: 10.1186/1744-859X-11-5.